<div><div></div><div><span><p><strong><span>Vax appointed James B. Breitmeyer, M.D., Ph.D. to its Board, effective immediately.</span></strong></p><div><table><tbody><tr><td><strong><span>Individual</span></strong></td><td><span>James B. Breitmeyer, M.D., Ph.D.</span></td></tr><tr><td><strong><span>Role</span></strong></td><td><span>Director</span></td></tr><tr><td><strong><span>Type of Change</span></strong></td><td><span>Appointed</span></td></tr><tr><td><strong><span>Effective Date</span></strong></td><td><span>April 23, 2026</span></td></tr><tr><td><strong><span>Reason</span></strong></td><td><span>Board appointment following recommendation by the Nominating and Governance Committee</span></td></tr><tr><td><strong><span>Replacement Info</span></strong></td><td><span>Not disclosed</span></td></tr><tr><td><strong><span>Background Details</span></strong></td><td><span>Current CEO and director of Altay Therapeutics; former CEO of Oncternal Therapeutics (2016–2025); extensive biotech executive experience in development and operations; M.D. and Ph.D.; board-certified in Internal Medicine and Oncology.</span></td></tr><tr><td><strong><span>Board/Committee Role Changes</span></strong></td><td><span>Board determined he meets independence standards; entitled to standard cash and equity director compensation and the company's indemnification agreement.</span></td></tr></tbody></table></div><p><span>Original SEC Filing: </span>Vaxart, Inc. [ VXRT ] - 8-K - Apr. 23, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

CYTOF

VXRT

SBIO

<p>Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current CEO of Altay Therapeutics and has extensive experience in the biotech sector. The Board has determined that he meets independence standards and will receive standard compensation and indemnification. This appointment follows a recommendation by the Nominating and Governance Committee.</p>

TradingView

ALTAMIRA THERAPEUTICS LTD

Vaxart

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

VG Health

ESC NEUBASE THERAPEUTI

Alta Equipment

Nano Labs

Plus Therapeutics

Oncolytics Biotech

Bavarian Nordic A/S

Nordic

NORDICUS PARTNERS CORP

Bitwise Avalanche ETF

Eli Lilly

Cadence Design

Cadence Capital Limited

Vertex Pharma

Axogen

Frontier, Inc. (Yamaguchi)

Change, Inc. (Japan)

OnKure Therapeutics

Tenon Medical

ALTA EQUIPMENT GROUP INC 10% DEP SH 1/1000TH CUM PFD SER A USD25

TENON MEDICAL INC C/WTS 16/06/2028 (TO PUR COM)

Vax appoints James B. Breitmeyer to its Board